Peri-interventional LiMAx test for liver ablation - A feasibility study
Karin Senk1, Carolina Rio Bartulos2, Juliane Wilcke3,4
1Institut für Röntgendiagnostik, Universitätsklinikum Regensburg, Regensburg, Germany.
Clinical Hemorheology and Microcirculation
|August 28, 2023
Summary
The liver maximum capacity (LiMAx) test effectively monitors liver function during and after ablation for liver cancer. It aids in assessing patient risk, with a cutoff value of 186μg/kg/h identified for critical post-intervention levels.
Area of Science:
- Hepatology
- Interventional Oncology
- Diagnostic Tools
Background:
- Local ablation is a key liver cancer treatment, particularly for cirrhosis.
- Advanced liver disease increases the risk of liver failure post-ablation.
- Current peri-interventional risk assessment lacks standardization.
Purpose of the Study:
- To evaluate the utility of peri-interventional liver maximum capacity (LiMAx) test measurements.
- To assess LiMAx in patients with primary or secondary liver cancer undergoing ablation.
- To explore LiMAx's role in risk stratification and monitoring.
Main Methods:
- Retrospective analysis of 49 patients undergoing liver ablation.
- LiMAx tests performed 24 hours pre- and post-ablation.
- Correlation of LiMAx values with MELD and ALBI scores.
Main Results:
- LiMAx values strongly correlated with MELD and ALBI scores pre-intervention.
- LiMAx reflected changes in liver function post-intervention.
- A cutoff LiMAx value of 186μg/kg/h predicted critical post-intervention liver levels.
Conclusions:
- The LiMAx test is a valuable tool for liver function monitoring during ablation.
- Peri-interventional LiMAx measurements can aid in pre-intervention risk assessment.
- LiMAx provides crucial insights into functional liver capacity in liver cancer patients.
